Apolizumab
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro[1][2].
Product Specifications
CAS Number
[267227-08-7]
Product Name Alternative
Hu1D10
UNSPSC
12352203
Target
Apoptosis
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/apolizumab.html
Solubility
10 mM in DMSO
Smiles
[Apolizumab]
References & Citations
[1]Thomas S Lin, et al. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec;50 (12) :1958-63.|[2]Matthew L. Hill DO, et al. In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines. Volume 106, Issue 11, 16 November 2005, Page 4826.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
216936 100 µg
SERPINA4 (Serpin Peptidase Inhibitor, Clade A (alpha-1 Antiproteinase, Antitrypsin), Member 4, Serpin-A4
Ask
View Details 303395 100 µg
IRAK2, CT (IRAK-2, Interleukin-1 Receptor-associated Kinase-like 2, Interleukin-1 Receptor-associated Kinase 2)
Ask
View Details 